

13 January 2026

Biologics Rheumatology

Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

• Abatacept [Orencia]	295
• Adalimumab [Humira]	230
• Adalimumab Biosimilars	986
• Apremilast [Otezla]	<5
• Baricitinib [Olumiant]	25
• Bimekizumab [Bimzelx]	39
• Certolizumab [Cimzia]	142
• Etanercept [Enbrel]	103
• Etanercept Biosimilars	356
• Filgotinib [Jyseleca]	<5
• Golimumab [Simponi]	93
• Guselkumab [Tremfya]	13
• Infliximab [Remicade]	69
• Infliximab Biosimilars	48
• Ixekizumab [Taltz]	140
• Risankizumab [Skyrizi]	<5
• Rituximab [MabThera]	70
• Rituximab Biosimilars	183
• Sarilumab [Kevzara]	<5
• Secukinumab [Cosentyx]	234
• Tocilizumab [Ro Actemra]	147
• Tocilizumab Biosimilars	<5
• Tofacitinib [Xeljanz]	23
• Upadacitinib [Rinvoq]	116
• Ustekinumab [Stelara]	<5
• Ustekinumab Biosimilar	<5

Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.